Xtacy Therapeutics Corp. (TSE:XTCY) has released an update.
Xtacy Therapeutics Corp. has announced the extension of the Management Cease Trade Order issued by the BCSC, which prohibits top management from trading company securities until financial documentation for specific periods is filed. The company expects to complete these filings by mid-April 2024 and has reported no significant business developments since its last interim report. Xtacy Therapeutics operates as a prospect generator in the wellness consumer products market, focusing on areas such as psychedelics, mycology, and hemp/CBD.
For further insights into TSE:XTCY stock, check out TipRanks’ Stock Analysis page.
